OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Drug: Sibeprenlimab 400 mgDrug: Placebo
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-03-26
- Target Recruit Count
- 530
- Registration Number
- NCT05248646
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
- Conditions
- Pulmonary TB
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 122
- Registration Number
- NCT05221502
- Locations
- πΏπ¦
Aurum Institute - Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
πΏπ¦TASK Applied Science, Brooklyn Chest Hospital Premises, Cape Town, South Africa
πΏπ¦University of CapeTown Lung Center Institute, Cape Town, South Africa
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Conditions
- Post-traumatic Stress Disorder (PTSD)
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-01-23
- Target Recruit Count
- 34
- Registration Number
- NCT05189977
- Locations
- πΊπΈ
For additional information regarding sites (California, Texas, New Jersey, Minnesota), Princeton, New Jersey, United States
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-09-01
- Target Recruit Count
- 147
- Registration Number
- NCT05113953
- Locations
- πΊπΈ
iResearch Atlanta, Decatur, Georgia, United States
πΊπΈPsych Atlanta, PC, Marietta, Georgia, United States
πΊπΈPrinceton Medical Institute, Princeton, New Jersey, United States
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2023-06-13
- Target Recruit Count
- 50
- Registration Number
- NCT05066724
- Locations
- πΊπΈ
Rose Research Center, Raleigh, North Carolina, United States
This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 18
- Registration Number
- NCT05015673
- Locations
- πΊπΈ
SDS Clinical Trials, Inc., Orange, California, United States
πΊπΈSleepMed of South Carolina, Columbia, South Carolina, United States
πΊπΈTodd Swick, MD PA, Houston, Texas, United States
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 21
- Registration Number
- NCT04865835
- Locations
- πΊπΈ
Hassman Research Institute, Marlton, New Jersey, United States
πΊπΈAt Fort Lauderdale Behavioral Health Center, Oakland Park, Florida, United States
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-02-02
- Target Recruit Count
- 122
- Registration Number
- NCT04830215
- Locations
- π¨π¦
Chatham-Kent Clinical Trials Research Centre, Chatham, Ontario, Canada
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-07-13
- Target Recruit Count
- 50
- Registration Number
- NCT04786730
- Locations
- πΊπΈ
For additional information regarding sites, contact 844-687-8522, San Antonio, Texas, United States
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Conditions
- Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-09-15
- Target Recruit Count
- 20
- Registration Number
- NCT04786574
- Locations
- πΊπΈ
Johns Hopkins Pediatric Specialty Clinic, Baltimore, Maryland, United States
πΊπΈNorthwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatology, Chicago, Illinois, United States
π¬π§Great Ormond Street, London, United Kingdom